Goldman Sachs’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-120,852
| Closed | -$32.6K | – | 5330 |
|
|
2025
Q1 | $32.6K | Buy |
+120,852
| New | +$32.6K | ﹤0.01% | 4953 |
|
|
2024
Q2 | – | Sell |
-118,243
| Closed | -$550K | – | 4885 |
|
|
2024
Q1 | $550K | Buy |
+118,243
| New | +$550K | ﹤0.01% | 3946 |
|
|
2023
Q4 | – | Sell |
-12,998
| Closed | -$39K | – | 4891 |
|
|
2023
Q3 | $39K | Sell |
12,998
-149,349
| -92% | -$448K | ﹤0.01% | 4510 |
|
|
2023
Q2 | $399K | Sell |
162,347
-37,477
| -19% | -$92.2K | ﹤0.01% | 4082 |
|
|
2023
Q1 | $452K | Sell |
199,824
-61,885
| -24% | -$140K | ﹤0.01% | 4123 |
|
|
2022
Q4 | $913K | Buy |
261,709
+190,362
| +267% | +$664K | ﹤0.01% | 3742 |
|
|
2022
Q3 | $2.64M | Sell |
71,347
-112,827
| -61% | -$4.18M | ﹤0.01% | 3148 |
|
|
2022
Q2 | $3.5M | Buy |
184,174
+154,883
| +529% | +$2.94M | ﹤0.01% | 2983 |
|
|
2022
Q1 | $791K | Sell |
29,291
-54,997
| -65% | -$1.49M | ﹤0.01% | 4279 |
|
|
2021
Q4 | $1.9M | Sell |
84,288
-1,794
| -2% | -$40.4K | ﹤0.01% | 3538 |
|
|
2021
Q3 | $2.26M | Buy |
86,082
+78,637
| +1,056% | +$2.06M | ﹤0.01% | 3389 |
|
|
2021
Q2 | $238K | Sell |
7,445
-3,239
| -30% | -$104K | ﹤0.01% | 4832 |
|
|
2021
Q1 | $376K | Sell |
10,684
-3,401
| -24% | -$120K | ﹤0.01% | 4525 |
|
|
2020
Q4 | $452K | Buy |
+14,085
| New | +$452K | ﹤0.01% | 3877 |
|
|
2020
Q2 | – | Sell |
-106,245
| Closed | -$3.62M | – | 4523 |
|
|
2020
Q1 | $3.62M | Buy |
106,245
+100,832
| +1,863% | +$3.44M | ﹤0.01% | 2439 |
|
|
2019
Q4 | $211K | Buy |
+5,413
| New | +$211K | ﹤0.01% | 3964 |
|